Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly
- PMID: 1530193
- DOI: 10.7326/0003-4819-117-8-625
Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly
Abstract
Objective: To evaluate the efficacy of adding intranasal live attenuated cold-adapted influenza A vaccine to inactivated influenza vaccine to prevent influenza A in elderly residents of long-term-care institutions.
Design: Randomized, double-blind, placebo-controlled study conducted over 3 years.
Setting: Three large nursing homes.
Participants: A total of 523 residents of nursing homes (mean age, 84.2 years).
Interventions: All participants received trivalent inactivated influenza vaccine parenterally and were randomly assigned to receive either live attenuated influenza A (H3N2) virus vaccine or placebo intranasally.
Measurements: Laboratory-documented influenza A was defined as a respiratory illness plus isolation of influenza A virus from nasal secretions, significant serologic response, or both. Participants were considered to have been exposed to influenza A if they resided in an institution in which cases of influenza A were documented. Outbreak-associated illnesses were defined as those occurring between the first and last isolation of influenza virus from within the institution, +/- 3 days.
Results: Participants who received intranasal vaccine and were subsequently exposed to influenza A had significantly lower rates of laboratory-documented influenza A (9 of 162 vaccine recipients compared with 24 of 169 placebo recipients; vaccine protective efficacy, 60.6%; 95% CI, 18% to 82%), outbreak-associated respiratory illnesses (13 of 162 vaccine recipients compared with 34 of 169 placebo recipients; vaccine protective efficacy, 56.8%; CI 23% to 76%), and outbreak-associated influenza-like illnesses (6 of 162 vaccine recipients compared with 18 of 169 placebo recipients; vaccine protective efficacy, 65.0%; CI 17% to 86%).
Conclusions: Intranasal immunization with live attenuated influenza A virus vaccine provided additional protection against influenza A when added to parenteral trivalent inactivated influenza vaccine among elderly nursing home residents.
Similar articles
-
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.JAMA. 1999 Jul 14;282(2):137-44. doi: 10.1001/jama.282.2.137. JAMA. 1999. PMID: 10411194 Clinical Trial.
-
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.Pediatrics. 2007 Sep;120(3):e553-64. doi: 10.1542/peds.2006-2836. Epub 2007 Aug 13. Pediatrics. 2007. PMID: 17698577 Clinical Trial.
-
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.J Clin Microbiol. 1991 Mar;29(3):498-505. doi: 10.1128/jcm.29.3.498-505.1991. J Clin Microbiol. 1991. PMID: 2037667 Free PMC article. Clinical Trial.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
Balancing the Efficacy and Safety of Vaccines in the Elderly.Open Longev Sci. 2012 Jun 29;6(2012):64-72. doi: 10.2174/1876326X01206010064. Open Longev Sci. 2012. PMID: 23565132 Free PMC article.
-
Pneumococcal and influenza vaccination: current situation and future prospects.Thorax. 2002 Oct;57 Suppl 2(Suppl 2):II24-II30. Thorax. 2002. PMID: 12364707 Free PMC article. Review. No abstract available.
-
Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.Drugs Aging. 1995 May;6(5):368-87. doi: 10.2165/00002512-199506050-00004. Drugs Aging. 1995. PMID: 7647426
-
Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.Immunology. 1996 Feb;87(2):179-85. doi: 10.1046/j.1365-2567.1996.462527.x. Immunology. 1996. PMID: 8698377 Free PMC article.
-
Respiratory viral infections in the elderly.Antiviral Res. 1999 Dec 15;44(2):79-102. doi: 10.1016/s0166-3542(99)00062-5. Antiviral Res. 1999. PMID: 10669259 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical